XtalPi and CK Life Sciences to collaborate in AI-empowered tumour vaccine research and development, opening a new paradigm for scientific innovation

Currently, there are only two cancer vaccines – sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for cervical cancer, as well as cancer vaccines against human papillomavirus and Hepatitis B is approved by the US Food and Drug Administration. FDA). More recently, several other cancer vaccines have entered clinical development and evidence of efficacy is beginning to emerge.

According to Mordor Intelligence, the size of the global cancer vaccine market US$6.79 billion in 2021 and will increase at a CAGR of 11.53% from 2022 to 2026. The expected market size by 2026 will be approx. US$12 billion.

Currently, the design and preclinical development process for cancer vaccines is complex and lengthy, hindering the efficiency and success rate of cancer vaccine research and development.

Incorporating XtalPi’s industry expertise in computational AI and robotics automation, this collaboration aims to build an AI cancer vaccine R&D platform that uses advanced AI algorithms and molecular modeling very accurate in predicting and designing cancer vaccines that can activate specific immune responses to attack. tumors. Cancer vaccines are screened and validated through automated assays, and by incorporating algorithmic feedback to optimize performance and efficacy, the project results in preclinical cancer vaccine candidate compounds with inhibitory activity. strong

Also Read :  Virtual teaching improves dental reality - UQ News

Dr. Huhao Wenthe founder and chairman of XtalPi, says: “As a company headquartered in the Hetao Shenzhen-Hong Kong Science and Technology Cooperation Zone, XtalPi makes every effort to achieve cooperation between Shenzhen a Hong Kong by creating new models for innovation in the Greater Bay Area. Empowered by recent technological advances in automation, artificial intelligence is rapidly expanding into new and diverse areas in drug research and development. Together with CK Life Sciences, we strive to overcome traditional limitations and discover diverse applications for new technologies. We believe that the AI ​​cancer vaccine platform jointly developed by CK Life Sciences and XtalPi will inspire the global scientific community to advance vaccine research and development and rapidly pursue breakthroughs. key to cancer vaccines. We believe this collaboration will greatly facilitate scientific research communication in the Greater Bay Area.”

Also Read :  How to set up a bedtime schedule on your Android device

Dr. Melvin TohVice President and Chief Scientific Officer of CK Life Sciences, says: “The R&D of tumor vaccines is one of the main development directions of CK Life Sciences. The collaboration with XtalPi will use XtalPi’s AI algorithm , molecular modeling and automated testing to speed up the R&D process, improve the success rate, and increase the efficacy of tumor vaccines.”

For XtalPi

Founded in 2014, the founders of XtalPi recognized a common obstacle for drug development related to solid polymorphism, which can be successfully addressed with quantum physics predictions. Since then, XtalPi has continued to identify and challenge traditional bottlenecks in biopharmaceutical R&D through innovative technologies. Through significant investments in engineering and personnel, XtalPi has four locations worldwide and approximately 1000 employees. XtalPi has entered into collaborative research with nearly all 20 pharmaceutical companies in the world. Its ID4 platform combines physics simulations with validation and refinement tests, automation for rapid synthesis, and machine learning to continuously improve predictive accuracy and efficiency.

Also Read :  When to listen to your customers and when not to?

For CK Life Sciences

CK Life Sciences (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission to improve the quality of life, CK Life Sciences is engaged in research and development, manufacturing, marketing, sales, sales and investment in products and materials. fall into three main categories – food products, medicine and agriculture. CK Life Sciences is a member of the CK Hutchison group.

Media contact:
Ruyu Wang
[email protected]
(617) 717-9867



Leave a Reply

Your email address will not be published.

Related Articles

Back to top button